{"transactions":[{"id":703085,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-28T01:14:06.000Z","date":"2026-07-27","kind":"other","planned":false,"acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred."}],"balance_after":2774980,"source":{"system":"sec-edgar","filing":"0001140361-26-029817","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126029817/form4.xml","form_type":"4"}},{"id":703083,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-27T23:59:55.000Z","date":"2026-07-27","kind":"other","planned":false,"acquired":false,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred."}],"balance_after":2818980,"source":{"system":"sec-edgar","filing":"0001140361-26-029791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126029791/form4.xml","form_type":"4"}},{"id":705918,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-20T18:55:54.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":10,"price":13.7,"value":137.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold."}],"balance_after":2857480,"source":{"system":"sec-edgar","filing":"0001140361-26-028955","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126028955/form4.xml","form_type":"4"}},{"id":707167,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-18T01:45:08.000Z","date":"2026-07-16","kind":"sale","planned":true,"acquired":false,"shares":10,"price":13.73,"value":137.3,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold."}],"balance_after":2857490,"source":{"system":"sec-edgar","filing":"0001140361-26-028846","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126028846/form4.xml","form_type":"4"}},{"id":721661,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-01T16:37:28.000Z","date":"2026-06-29","kind":"other","planned":false,"acquired":false,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 2,933,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 76,000 shares transferred."}],"balance_after":2857500,"source":{"system":"sec-edgar","filing":"0001140361-26-027140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126027140/form4.xml","form_type":"4"}},{"id":732484,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-06-19T01:59:08.000Z","date":"2026-06-15","kind":"other","planned":false,"acquired":false,"shares":66500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 3,000,000 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 66,500 shares transferred. All shares are held directly and registered in the name of the Reporting Person."}],"balance_after":2933500,"source":{"system":"sec-edgar","filing":"0001140361-26-025796","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126025796/form4.xml","form_type":"4"}}]}